Valeritas raising $45M to market disposable insulin pump

V-Go Disposable Insulin Delivery Device--Courtesy of Valeritas

Cash-hungry disposable insulin device maker Valeritas is raising $45 million in venture capital, according to an SEC filing. That could push the total amount the company's raised to more than $305 million since it was founded in 2006.

The startup needs this money to fund commercialization of its V-Go product, a disposable insulin dispenser for adult diabetics that provides a continuous insulin stream for 24 hours and on-demand mealtime dosing. The FDA cleared the device in 2010 for this indication and then later in 2011 cleared it specifically for use with Novo Nordisk's ($NVO) NovoLog. V-Go also received a CE mark in 2011.

The most recent data from Valeritas were presented in May at the American Association of Clinical Endocrinologists conference. These interim data from the SIMPLE study, a prospective observational trial, showed that Type 2 diabetes patients who switched to V-Go from long-acting insulin (with or without additional oral medications) had significantly improved glycemic control and a reduction of total daily insulin dose. Included in the interim analysis were 40 patients who used the V-Go for a minimum of 6 months; average A1C levels fell to a range of 7.7% to 8.3% from 8.5% to 10.2%.

The V-Go is 2.4 x 1.3 x 0.5 inches and weighs about one ounce when filled with insulin. It comes in three sizes and must be filled by the patient with fast-acting insulin. It is attached via adhesive to tissue on the abdomen or the back of the arm. One newly filled V-Go lasts 24 hours.

In this latest financing, Valeritas has raised almost $22 million of what looks to be a planned $45 million Series D round. Disclosed investors in the new round so far include existing investors Welsh, Carson, Anderson & Stowe, MPM Asset Management, Pitango Venture Capital and Onset Ventures. Investors in prior rounds include Abingworth, Kaiser Permanente Ventures and Advanced Technology Ventures.

Valeritas raised a $150 million Series C round in September 2011 and a $10 million Series B round in April 2011. Most recently in 2013, it raised up to $100 million in debt from Capital Royalty.

- here is the SEC filing

Special Report: Top medical device VC investments of 2012

Suggested Articles

Johnson & Johnson Vision announced that the worldwide president of its surgical business, Tom Frinzi, plans to retire at the end of this year.

Philips looked back on 15 years of data from one of its telehealth-equipped intensive care units, where centralizing operations reduced mortality.

Sanofi will look to pull back from its three-year-old relationship with Verily and their virtual diabetes clinic, Onduo.